Nearly 1 in 4 people with NPM1-mutated acute myeloid leukemia (AML) achieved complete remission after treatment with ziftomenib in a Phase 2 clinical trial. Dubbed…
News
Actuate Therapeutics’ treatment candidate elraglusib significantly lowered the risk of death — about doubling one-year survival rates — among people with an advanced form…
A young girl with an unusual form of low-grade glioma, a type of brain tumor, responded well to standard chemotherapy, emphasizing the value of…
Relacorilant lowered the risk of disease progression and death by about 30% when used on top of standard chemotherapy in people with platinum-resistant ovarian cancer.
One-third of patients with hard-to-treat myeloma were alive and free from disease progression five years after a single infusion of the cell therapy Carvykti…
A team led by a Rice University researcher received a grant to investigate treatments targeting mitochondria for acute amyloid leukemia (AML), a type of…
Combining chemotherapy with focused ultrasound and microbubbles is safe and helps deliver chemotherapy drugs more effectively to tumors in people with inoperable pancreatic ductal adenocarcinoma…
Data from a clinical trial show the experimental treatment lucicebtide has so far been well tolerated in people with glioblastoma, an aggressive type of…
A committee of the European Medicines Agency has recommended approving GSK’s Blenrep (belantamab mafodotin) in combination with other therapeutic agents to treat relapsed or refractory…
The first participant in a U.S. Phase 1 clinical trial testing T-cell therapy candidate CER-1236 — Cero Therapeutics’ treatment for people with acute myeloid…
